Phase 1 Liver Disease Clinical Trials
30 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 30 trials
Recruiting
Phase 1
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
Liver DiseasesHepatic Insufficiency
Incyte Corporation16 enrolled4 locationsNCT07559474
Recruiting
Phase 1
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline32 enrolled3 locationsNCT07358546
Recruiting
Phase 1
Evaluating the Pharmacokinetics and Safety of Miricorilant
Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663
Recruiting
Phase 1Phase 2
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
CirrhosisAlcohol Use DisorderLiver Disease; Alcohol-Related
Virginia Commonwealth University80 enrolled2 locationsNCT05548452
Recruiting
Phase 1
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
Alcohol Associated Liver DiseaseHeavy Drinking Behavior
National Institute on Alcohol Abuse and Alcoholism (NIAAA)100 enrolled1 locationNCT04781322
Recruiting
Phase 1Phase 2
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis
Regeneron Pharmaceuticals132 enrolled3 locationsNCT06836609
Recruiting
Phase 1Phase 2
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Healthy VolunteersMetabolic dysfunction–associated steatotic liver disease (MASLD)
Regeneron Pharmaceuticals172 enrolled6 locationsNCT05648214
Recruiting
Phase 1
Effect of Insulin Lowering on Lipogenesis
ObesityInsulin ResistanceNon-Alcoholic Fatty Liver Disease+2 more
Columbia University25 enrolled1 locationNCT07403604
Recruiting
Phase 1
Human Models of Selective Insulin Resistance: Alpelisib, Part I
Insulin ResistanceNon-Alcoholic Fatty Liver DiseaseOverweight and Obesity+1 more
Columbia University32 enrolled1 locationNCT06354088
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline30 enrolled1 locationNCT07335198
Recruiting
Phase 1
Developing Microbial Therapy for MASLD: From Mechanism to Clinical Validation
Metabolic Dysfunction-Associated Steatotic Liver Disease
Leeuwenhoek Laboratories Co. Ltd.40 enrolled1 locationNCT07488975
Recruiting
Phase 1Phase 2
Immune Tolerance Induction After Liver Transplantation
Liver TransplantationEnd Stage Liver DiseaseImmune Tolerance+6 more
University of California, Los Angeles12 enrolled1 locationNCT07269041
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Thrombocytopenia Associated With Chronic Liver Disease
Chongqing Peg-Bio Biopharm Co., Ltd.54 enrolled8 locationsNCT07446491
Recruiting
Phase 1
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
CirrhosisCholestatic Liver DiseaseHepatic Impairment
Zydus Therapeutics Inc.30 enrolled1 locationNCT05045482
Recruiting
Phase 1
A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
Fatty Liver Disease
Novo Nordisk A/S60 enrolled1 locationNCT07214870
Recruiting
Phase 1
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Nonalcoholic Steatohepatitis (NASH)Metabolic dysfunction-associated steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease NAFLD+1 more
Corcept Therapeutics8 enrolled1 locationNCT06947304
Recruiting
Phase 1Phase 2
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
Liver DiseasesCirrhosis, LiverDecompensated Liver Cirrhosis+5 more
Resolution Therapeutics Limited30 enrolled14 locationsNCT06823713
Recruiting
Phase 1
A Study of SIPLIZUMAB in AILD and LT Patients
Autoimmune HepatitisCirrhosis, LiverPrimary Sclerosing Cholangitis+3 more
Elizabeth C. Verna8 enrolled1 locationNCT06455280
Recruiting
Phase 1
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
Liver DiseasesCirrhosis, LiverLiver Failure
University of Chicago24 enrolled1 locationNCT06871111
Recruiting
Phase 1
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
Cholestatic Liver Disease
Zydus Therapeutics Inc.6 enrolled1 locationNCT06825559